.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,550,153

« Back to Dashboard

Claims for Patent: 7,550,153

Title:Pantoprazole multiparticulate formulations
Abstract:Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose(hypromellose) and water, an enteric coat on the sub-coat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose(hypromellose) and water.
Inventor(s): Venkata Ramana Rao; Sripriya (Mahwah, NJ), Shah; Syed M. (East Hanover, NJ), Tatapudy; Hanumantharao (Suffern, NY), Saunders; Richard William (Palisades, NY), Fawzi; Mahdi (Morristown, NJ), Nagi; Arwinder (Thiells, NY), Singh; Shailesh (Bardonia, NY), Hasan; Sumon A (Monroe, NY)
Assignee: Wyeth (Madison, NJ)
Application Number:11/731,474
Patent Claims: 1. A method of treating ulcers of the stomach and duodenum, gastroesophageal reflux disease (GERD), or Zollinger-Ellison Syndrome in a mammalian subject, comprising the step of administering to the subject a plurality of pantoprazole multiparticulates, each of which comprise: a core consisting of about 45% w/w pantoprazole sodium sesquihydrate and one or more excipients comprising about 25% to 30% w/w microcrystalline cellulose, about 4% to 6% w/w polysorbate 80, about 14% to 16% w/w crospovidone, about 0.5 to 2% w/w hydroxypropyl methylcellulose, about 5% to 8% w/w sodium carbonate, and about 1 to about 2% water; an initial seal coat comprising hydroxypropylmethyl cellulose on the spheroid core; and an enteric coat on the initial coated spheroid core, wherein the multiparticulates have an average size in the range from about 0.7 mm to about 1.25 mm.

2. The method according to claim 1, wherein the mammalian subject is a human.

3. The method according to claim 1, wherein said plurality of multiparticulates comprises a pantoprazole compound present in an amount of about 40 mg of pantoprazole per 100 mg uncoated multiparticulates.

4. The method according to claim 1, wherein the multiparticulates have an average diameter of about 1 mm.

5. The method according to claim 1, wherein said enteric coat comprises a copolymer of methacrylic acid and methacrylates

6. The method according to claim 5, wherein the enteric coat comprises about 48% w/w of the coated multiparticulates.

7. The method according to claim 1, further comprising a final seal coat on the enteric coat.

8. The method according to claim 7, wherein the final seal coat comprises about 0.1 to 10 wt% of the multiparticulates.

9. The method according to claim 7, wherein the final seal coat comprises hydroxypropyl methyl cellulose (hypromellose).

10. The method according to claim 1 wherein said initial seal coat is in the range of about 2 to 4% w/w of the weight of the uncoated core.

11. The method according to claim 1, wherein the initial seal coat comprises hypromellose.

12. The method according to claim 1, wherein the spheroid tore consists essentially of: TABLE-US-00013 pantoprazole sodium sesquihydrate 45% w/w microcrystalline cellulose 27% w/w polysorbate 80 5% w/w crospovidone 15% w/w hydroxypropylmethylcellulose 1% w/w, and sodium carbonate 7% w/w.

13. The method according to claim 1, wherein the enteric coating comprises a copolymer of merhaczylic acid and methyacrylates and further comprising an outer seal coat comprising hydroxypropylmethyl cellulose and wherein the multiparticulates have an average diameter of about 1 mm.

14. The method according to claim 1, wherein the enteric coat comprises about 48% w/w of the multiparticulates.

15. The method according to claim 1, wherein the enteric coating comprises about 30% w/w of the copolymer of methacrylic acid and methacrylate, about 15% w/w talc, about 3% triethyl citrate and a pH adjuster; said amounts being by weight of the multiparticulates.

16. The method according to claim 1, wherein the multiparticulates are administered in a food.

17. The method according to claim 16 wherein the food is applesauce.

18. The method according to claim 1, wherein the multiparticulates are administered in a physiologically compatible liquid.

19. The method according to claim 1, wherein the multiparticulates are contained in a foil wrapper prior to administration.

20. The method according to claim 1, wherein the multiparticulates are administered in a capsule.

21. The method according to claim 1, wherein the spheroid core consists essentially of: TABLE-US-00014 pantoprazole sodium sesquihydrate about 45% w/w microcrystalline cellulose about 27% w/w polysorbate 80 about 5% w/w crospovidone about 15% w/w hydroxypropylmethylcellulose about 1% w/w, sodium carbonate about 6.5% w/w, and water.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc